Marvel Biosciences Corp. (MRVL.V)
CAD 0.16
(10.34%)
CAD 0.16
(10.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.25 Million CAD | 11.47% |
| 2022 | -2.5 Million CAD | -415.41% |
| 2021 | -1.24 Million CAD | 184.56% |
| 2020 | -1.01 Million CAD | -853.31% |
| 2019 | -100.05 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -237.74 Thousand CAD | -29.42% |
| 2024 Q2 | -252 Thousand CAD | 57.72% |
| 2024 Q1 | -439.74 Thousand CAD | 51.86% |
| 2023 Q2 | -230.48 Thousand CAD | 18.56% |
| 2023 FY | - CAD | 11.47% |
| 2023 Q3 | -692.84 Thousand CAD | -200.6% |
| 2023 Q4 | -1.03 Million CAD | -49.6% |
| 2023 Q1 | -283.03 Thousand CAD | 51.37% |
| 2022 Q1 | -509.9 Thousand CAD | -134.89% |
| 2022 FY | - CAD | -415.41% |
| 2022 Q4 | -582 Thousand CAD | -49.7% |
| 2022 Q2 | -1.06 Million CAD | -108.49% |
| 2022 Q3 | -388.79 Thousand CAD | 63.43% |
| 2021 Q2 | -172.01 Thousand CAD | 52.94% |
| 2021 Q1 | -365.5 Thousand CAD | 0.0% |
| 2021 FY | - CAD | 184.56% |
| 2021 Q3 | -253.64 Thousand CAD | -47.45% |
| 2021 Q4 | 1.46 Million CAD | 676.18% |
| 2020 FY | - CAD | -853.31% |
| 2019 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Arch Biopartners Inc. | -430.71 Thousand CAD | -422.85% |
| Covalon Technologies Ltd. | -3.49 Million CAD | 35.502% |
| Hemostemix Inc. | -1.94 Million CAD | -15.739% |
| Universal Ibogaine Inc. | -4.6 Million CAD | 51.122% |
| Kane Biotech Inc. | -3.23 Million CAD | 30.373% |
| MedMira Inc. | -1.57 Million CAD | -42.782% |
| NervGen Pharma Corp. | -17.72 Million CAD | 87.292% |
| XORTX Therapeutics Inc. | -6.46 Million CAD | 65.186% |